The Genetic Algorithm That Revealed My Possible Babies
By Rachel Lehmann-Haupt,
Neo.Life [cites Marcy Darnovsky]
| 05. 04. 2017
Seeing a thousand of my potential progeny gave me a glimpse of new things that future parents will stress over.
“It is likely that within a few decades, people will look back on our current circumstance with a sense of disbelief that we screened for so few conditions. They will also be puzzled and dismayed, as I am now, that our healthcare system put so many couples in an unnecessarily difficult position, by not identifying their carrier status until a pregnancy was already underway.” — Francis Collins, Director of the National Institutes of Health
“Striving to better, oft we mar what’s well.” — William Shakespeare, King Lear
Lee Silver, the co-founder and chief science officer of GenePeeks, is tough to pin down. He admits he has severe ADD that makes it hard for him to focus for hours or even minutes. He certainly doesn’t like to stick with a job for more than a few years. “I get bored with things,” he says. GenePeeks arose during one of Silver’s flights of boredom. But the idea at its core is so big that he’s still at...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...